Crinetics Pharmaceuticals shares are trading higher after UBS initiated coverage on the stock with a Buy rating and announced a $55 price ta
Crinetics Pharmaceuticals shares are trading higher after UBS initiated coverage on the stock with a Buy rating and announced a $55 price target.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.